{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:16:02Z","timestamp":1790799362131,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Otorhinolaryngol"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s00405-022-07762-4","type":"journal-article","created":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T18:41:37Z","timestamp":1669920097000},"page":"2309-2316","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Chronic rhinosinusitis with nasal polyps management in the biologic therapy era: an international YO-IFOS survey"],"prefix":"10.1007","volume":"280","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3588-9095","authenticated-orcid":false,"given":"Juan","family":"Maza-Solano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3768-6216","authenticated-orcid":false,"given":"Ameen","family":"Biadsee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5825-2759","authenticated-orcid":false,"given":"Leigh J.","family":"Sowerby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3580-0967","authenticated-orcid":false,"given":"Christian","family":"Calvo-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6463-1459","authenticated-orcid":false,"given":"Manuel","family":"Tucciarone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6190-1425","authenticated-orcid":false,"given":"Taciano","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1251-0185","authenticated-orcid":false,"given":"Antonino","family":"Maniaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1457-6871","authenticated-orcid":false,"given":"Alberto Maria","family":"Saibene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9454-9464","authenticated-orcid":false,"given":"Carlos M.","family":"Chiesa-Estomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5939-5372","authenticated-orcid":false,"given":"Thomas","family":"Radulesco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4470-7329","authenticated-orcid":false,"given":"Osama","family":"Metwaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0845-0845","authenticated-orcid":false,"given":"Jerome R.","family":"Lechien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7204-5599","authenticated-orcid":false,"given":"Isam","family":"Alobid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1879-5580","authenticated-orcid":false,"given":"Luca Giovanni","family":"Locatello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,1]]},"reference":[{"issue":"9","key":"7762_CR1","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/alr.22633","volume":"10","author":"LT Roland","year":"2020","unstructured":"Roland LT, Smith TL, Schlosser RJ et al (2020) Guidance for contemporary use of biologics in management of chronic rhinosinusitis with nasal polyps: discussion from a National Institutes of Health-sponsored workshop. Int Forum Allergy Rhinol 10(9):1037\u20131042. https:\/\/doi.org\/10.1002\/alr.22633","journal-title":"Int Forum Allergy Rhinol"},{"issue":"3","key":"7762_CR2","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/alr.22741","volume":"11","author":"RR Orlandi","year":"2021","unstructured":"Orlandi RR, Kingdom TT, Smith TL et al (2021) International consensus statement on allergy and rhinology: rhinosinusitis 2021. Int Forum Allergy Rhinol 11(3):213\u2013739. https:\/\/doi.org\/10.1002\/alr.22741","journal-title":"Int Forum Allergy Rhinol"},{"issue":"S29","key":"7762_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4193\/Rhin20.600","volume":"58","author":"WJ Fokkens","year":"2020","unstructured":"Fokkens WJ, Lund VJ, Hopkins C et al (2020) European position paper on rhinosinusitis and nasal polyps 2020. Rhinology 58(S29):1\u2013464. https:\/\/doi.org\/10.4193\/Rhin20.600","journal-title":"Rhinology"},{"issue":"12","key":"7762_CR4","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1111\/all.13875","volume":"74","author":"WJ Fokkens","year":"2019","unstructured":"Fokkens WJ, Lund V, Bachert C et al (2019) EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy 74(12):2312\u20132319. https:\/\/doi.org\/10.1111\/all.13875","journal-title":"Allergy"},{"issue":"1","key":"7762_CR5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40463-021-00493-2","volume":"50","author":"A Thamboo","year":"2021","unstructured":"Thamboo A, Kilty S, Witterick I et al (2021) Canadian Rhinology Working Group consensus statement: biologic therapies for chronic rhinosinusitis. J Otolaryngol Head Neck Surg 50(1):15. https:\/\/doi.org\/10.1186\/s40463-021-00493-2","journal-title":"J Otolaryngol Head Neck Surg"},{"issue":"10209","key":"7762_CR6","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","volume":"394","author":"C Bachert","year":"2019","unstructured":"Bachert C, Han JK, Desrosiers M et al (2019) Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 394(10209):1638\u20131650. https:\/\/doi.org\/10.1016\/S0140-6736(19)31881-1","journal-title":"Lancet"},{"issue":"3","key":"7762_CR7","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","volume":"146","author":"P Gevaert","year":"2020","unstructured":"Gevaert P, Omachi TA, Corren J et al (2020) Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol 146(3):595\u2013605. https:\/\/doi.org\/10.1016\/j.jaci.2020.05.032","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"7762_CR8","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","volume":"9","author":"JK Han","year":"2021","unstructured":"Han JK, Bachert C, Fokkens W et al (2021) Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 9(10):1141\u20131153. https:\/\/doi.org\/10.1016\/S2213-2600(21)00097-7","journal-title":"Lancet Respir Med"},{"issue":"4","key":"7762_CR9","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.jaci.2021.08.030","volume":"149","author":"C Bachert","year":"2022","unstructured":"Bachert C, Han JK, Desrosiers MY et al (2022) Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial. J Allergy Clin Immunol 149(4):1309-1317.e12. https:\/\/doi.org\/10.1016\/j.jaci.2021.08.030","journal-title":"J Allergy Clin Immunol"},{"key":"7762_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/alr.23039","author":"A Biadsee","year":"2022","unstructured":"Biadsee A, Payne S, Sowerby LJ (2022) Can we make biologic therapy more affordable? Int Forum Allergy Rhinol. https:\/\/doi.org\/10.1002\/alr.23039","journal-title":"Int Forum Allergy Rhinol"},{"key":"7762_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/lary.29992","author":"AR Swisher","year":"2021","unstructured":"Swisher AR, Kshirsagar RS, Adappa ND, Liang J (2021) Dupilumab adverse events in nasal polyp treatment: analysis of FDA adverse event reporting system. Laryngoscope. https:\/\/doi.org\/10.1002\/lary.29992","journal-title":"Laryngoscope"},{"issue":"10","key":"7762_CR12","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1007\/s11606-021-06737-1","volume":"36","author":"A Sharma","year":"2021","unstructured":"Sharma A, Minh Duc NT, Luu Lam Thang T et al (2021) A consensus-based checklist for reporting of survey studies (CROSS). J Gen Intern Med 36(10):3179\u20133187. https:\/\/doi.org\/10.1007\/s11606-021-06737-1","journal-title":"J Gen Intern Med"},{"issue":"1","key":"7762_CR13","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/alr.22888","volume":"12","author":"M Liu","year":"2022","unstructured":"Liu M, Liu J, Weitzel EK, Chen PG (2022) The predictive utility of the 22-item sino-nasal outcome test (SNOT-22): a scoping review. Int Forum Allergy Rhinol 12(1):83\u2013102. https:\/\/doi.org\/10.1002\/alr.22888","journal-title":"Int Forum Allergy Rhinol"},{"issue":"6 Suppl","key":"7762_CR14","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jaci.2004.09.029","volume":"114","author":"EO Meltzer","year":"2004","unstructured":"Meltzer EO, Hamilos DL, Hadley JA et al (2004) Rhinosinusitis: establishing definitions for clinical research and patient care. J Allergy Clin Immunol 114(6 Suppl):155\u2013212. https:\/\/doi.org\/10.1016\/j.jaci.2004.09.029","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"7762_CR15","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1002\/lary.24654","volume":"124","author":"AJ Psaltis","year":"2014","unstructured":"Psaltis AJ, Li G, Vaezeafshar R, Cho KS, Hwang PH (2014) Modification of the Lund-Kennedy endoscopic scoring system improves its reliability and correlation with patient-reported outcome measures. Laryngoscope 124(10):2216\u20132223. https:\/\/doi.org\/10.1002\/lary.24654","journal-title":"Laryngoscope"},{"issue":"1","key":"7762_CR16","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1148\/radiol.2016152230","volume":"281","author":"WT O'Brien Sr","year":"2016","unstructured":"O\u2019Brien WT Sr, Hamelin S, Weitzel EK (2016) The preoperative sinus CT: avoiding a \u201cCLOSE\u201d call with surgical complications. Radiology 281(1):10\u201321. https:\/\/doi.org\/10.1148\/radiol.2016152230","journal-title":"Radiology"},{"key":"7762_CR17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.4193\/RHINOL\/18.054","volume":"1","author":"JM Maza-Solano","year":"2018","unstructured":"Maza-Solano JM, Gonz\u00e1lez-Garc\u00eda J, Moreno-Luna R, Ambrosiani-Fern\u00e1ndez J, Dom\u00ednguez-Dur\u00e1n E, S\u00e1nchez-G\u00f3mez S (2018) \u201cABCDEF Checklist\u201d based on 3D radiological images for preoperative planning of endoscopic sinus surgery. Rhinology Online 1:133\u2013142. https:\/\/doi.org\/10.4193\/RHINOL\/18.054","journal-title":"Rhinology Online"},{"issue":"6","key":"7762_CR18","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/j.jaip.2022.01.016","volume":"10","author":"AR Sedaghat","year":"2022","unstructured":"Sedaghat AR, Kuan EC, Scadding GK (2022) Epidemiology of chronic rhinosinusitis: prevalence and risk factors. J Allergy Clin Immunol Pract 10(6):1395\u20131403. https:\/\/doi.org\/10.1016\/j.jaip.2022.01.016","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"7762_CR19","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1016\/j.jaip.2019.05.009","volume":"7","author":"WW Stevens","year":"2019","unstructured":"Stevens WW, Peters AT, Tan BK et al (2019) Associations between inflammatory endotypes and clinical presentations in chronic rhinosinusitis. J Allergy Clin Immunol Pract 7(8):2812-2820.e3. https:\/\/doi.org\/10.1016\/j.jaip.2019.05.009","journal-title":"J Allergy Clin Immunol Pract"},{"key":"7762_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/cea.14153","author":"A Matucci","year":"2022","unstructured":"Matucci A, Nencini F, Maggiore G et al (2022) High proportion of inflammatory CD62Llow eosinophils in blood and nasal polyps of severe asthma patients. Clin Exp Allergy. https:\/\/doi.org\/10.1111\/cea.14153","journal-title":"Clin Exp Allergy"},{"issue":"6","key":"7762_CR21","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1016\/j.jaip.2022.01.013","volume":"10","author":"WJ Fokkens","year":"2022","unstructured":"Fokkens WJ, Lund V, Luong AU, Orlandi RR (2022) A comparison of international guidelines for rhinosinusitis. J Allergy Clin Immunol Pract 10(6):1418\u20131422. https:\/\/doi.org\/10.1016\/j.jaip.2022.01.013","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"7762_CR22","doi-asserted-by":"publisher","DOI":"10.2196\/15588","volume":"3","author":"J Meirte","year":"2020","unstructured":"Meirte J, Hellemans N, Anthonissen M et al (2020) Benefits and disadvantages of electronic patient-reported outcome measures: systematic review. JMIR Perioper Med 3(1):e15588. https:\/\/doi.org\/10.2196\/15588","journal-title":"JMIR Perioper Med"},{"issue":"2","key":"7762_CR23","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/cea.12880","volume":"47","author":"D Robinson","year":"2017","unstructured":"Robinson D, Humbert M, Buhl R et al (2017) Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clin Exp Allergy 47(2):161\u2013175. https:\/\/doi.org\/10.1111\/cea.12880","journal-title":"Clin Exp Allergy"},{"issue":"3","key":"7762_CR24","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.jaip.2020.09.063","volume":"9","author":"TM Laidlaw","year":"2021","unstructured":"Laidlaw TM, Mullol J, Woessner KM, Amin N, Mannent LP (2021) Chronic rhinosinusitis with nasal polyps and asthma. J Allergy Clin Immunol Pract 9(3):1133\u20131141. https:\/\/doi.org\/10.1016\/j.jaip.2020.09.063","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"9","key":"7762_CR25","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1002\/alr.21979","volume":"7","author":"E De Corso","year":"2017","unstructured":"De Corso E, Lucidi D, Battista M et al (2017) Prognostic value of nasal cytology and clinical factors in nasal polyps development in patients at risk: can the beginning predict the end? Int Forum Allergy Rhinol 7(9):861\u2013867. https:\/\/doi.org\/10.1002\/alr.21979","journal-title":"Int Forum Allergy Rhinol"},{"issue":"S28","key":"7762_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4193\/Rhin19.410","volume":"57","author":"J Rimmer","year":"2019","unstructured":"Rimmer J, Hellings P, Lund VJ et al (2019) European position paper on diagnostic tools in rhinology. Rhinology 57(S28):1\u201341. https:\/\/doi.org\/10.4193\/Rhin19.410","journal-title":"Rhinology"},{"issue":"3","key":"7762_CR27","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/coa.13524","volume":"45","author":"ML Coates","year":"2020","unstructured":"Coates ML, Martinez Del Pero M (2020) Updates in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis for the ENT surgeon. Clin Otolaryngol 45(3):316\u2013326. https:\/\/doi.org\/10.1111\/coa.13524","journal-title":"Clin Otolaryngol"},{"issue":"3","key":"7762_CR28","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jacig.2022.03.006","volume":"1","author":"K Yamazaki","year":"2022","unstructured":"Yamazaki K, Nomizo T, Hatanaka K et al (2022) Eosinophilic granulomatosis with polyangiitis after treatment with dupilumab. J Allergy Clin Immunol 1(3):180\u2013182. https:\/\/doi.org\/10.1016\/j.jacig.2022.03.006","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"7762_CR29","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1177\/0145561320964653","volume":"100","author":"GB Patel","year":"2021","unstructured":"Patel GB, Peters AT (2021) The role of biologics in chronic rhinosinusitis with nasal polyps. Ear Nose Throat J 100(1):44\u201347. https:\/\/doi.org\/10.1177\/0145561320964653","journal-title":"Ear Nose Throat J"},{"issue":"5","key":"7762_CR30","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/j.1749-4486.2006.01275.x","volume":"31","author":"C Hopkins","year":"2006","unstructured":"Hopkins C, Browne JP, Slack R et al (2006) The national comparative audit of surgery for nasal polyposis and chronic rhinosinusitis. Clin Otolaryngol 31(5):390\u2013398. https:\/\/doi.org\/10.1111\/j.1749-4486.2006.01275.x","journal-title":"Clin Otolaryngol"},{"issue":"3","key":"7762_CR31","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1177\/0194599818773065","volume":"159","author":"PT Le","year":"2018","unstructured":"Le PT, Soler ZM, Jones R, Mattos JL, Nguyen SA, Schlosser RJ (2018) Systematic review and meta-analysis of SNOT-22 outcomes after surgery for chronic rhinosinusitis with nasal polyposis. Otolaryngol Head Neck Surg 159(3):414\u2013423. https:\/\/doi.org\/10.1177\/0194599818773065","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"3","key":"7762_CR32","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1159\/000519228","volume":"183","author":"Q Wu","year":"2022","unstructured":"Wu Q, Zhang Y, Kong W et al (2022) Which is the best biologic for nasal polyps: dupilumab, omalizumab, or mepolizumab? A network meta-analysis. Int Arch Allergy Immunol 183(3):279\u2013288. https:\/\/doi.org\/10.1159\/000519228","journal-title":"Int Arch Allergy Immunol"},{"key":"7762_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/alr.23035","author":"ES Longino","year":"2022","unstructured":"Longino ES, Labby AB, Wu J et al (2022) Association of cytokine profile with prior treatment failure and revision surgery in chronic rhinosinusitis. Int Forum Allergy Rhinol. https:\/\/doi.org\/10.1002\/alr.23035","journal-title":"Int Forum Allergy Rhinol"},{"issue":"2","key":"7762_CR34","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/alr.22652","volume":"11","author":"N Chapurin","year":"2021","unstructured":"Chapurin N, Li P, Chandra RK, Turner JH, Chowdhury NI (2021) Elevated mucus interleukin-17A levels are associated with increased prior sinus surgery for chronic rhinosinusitis. Int Forum Allergy Rhinol 11(2):120\u2013127. https:\/\/doi.org\/10.1002\/alr.22652","journal-title":"Int Forum Allergy Rhinol"},{"key":"7762_CR35","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2147\/TCRM.S210648","volume":"16","author":"J Kim","year":"2020","unstructured":"Kim J, Naclerio R (2020) Therapeutic potential of dupilumab in the treatment of chronic rhinosinusitis with nasal polyps: evidence to date. Ther Clin Risk Manag 16:31\u201337. https:\/\/doi.org\/10.2147\/TCRM.S210648","journal-title":"Ther Clin Risk Manag"},{"key":"7762_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/alr.22951","author":"H Dharmarajan","year":"2021","unstructured":"Dharmarajan H, Falade O, Lee SE, Wang EW (2021) Outcomes of dupilumab treatment versus endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol. https:\/\/doi.org\/10.1002\/alr.22951","journal-title":"Int Forum Allergy Rhinol"},{"issue":"1","key":"7762_CR37","doi-asserted-by":"publisher","first-page":"E26","DOI":"10.1002\/lary.28648","volume":"131","author":"GA Scangas","year":"2021","unstructured":"Scangas GA, Wu AW, Ting JY et al (2021) Cost utility analysis of dupilumab versus endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps. Laryngoscope 131(1):E26\u2013E33. https:\/\/doi.org\/10.1002\/lary.28648","journal-title":"Laryngoscope"},{"issue":"15","key":"7762_CR38","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1001\/jama.282.15.1458","volume":"282","author":"MD Cabana","year":"1999","unstructured":"Cabana MD, Rand CS, Powe NR et al (1999) Why don\u2019t physicians follow clinical practice guidelines? A framework for improvement. JAMA 282(15):1458\u20131465. https:\/\/doi.org\/10.1001\/jama.282.15.1458","journal-title":"JAMA"},{"issue":"3 Suppl","key":"7762_CR39","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.otohns.2007.06.726","volume":"137","author":"RM Rosenfeld","year":"2007","unstructured":"Rosenfeld RM, Andes D, Bhattacharyya N et al (2007) Clinical practice guideline: adult sinusitis. Otolaryngol Head Neck Surg 137(3 Suppl):S1\u2013S31. https:\/\/doi.org\/10.1016\/j.otohns.2007.06.726","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"1","key":"7762_CR40","doi-asserted-by":"publisher","first-page":"22958","DOI":"10.3402\/jchimp.v4.22958","volume":"4","author":"R Alweis","year":"2014","unstructured":"Alweis R, Greco M, Wasser T, Wenderoth S (2014) An initiative to improve adherence to evidence-based guidelines in the treatment of URIs, sinusitis, and pharyngitis. J Community Hosp Intern Med Perspect 4(1):22958. https:\/\/doi.org\/10.3402\/jchimp.v4.22958","journal-title":"J Community Hosp Intern Med Perspect"},{"issue":"11","key":"7762_CR41","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1023\/A:1020016922473","volume":"17","author":"K Korkeila","year":"2001","unstructured":"Korkeila K, Suominen S, Ahvenainen J et al (2001) Non-response and related factors in a nation-wide health survey. Eur J Epidemiol 17(11):991\u2013999. https:\/\/doi.org\/10.1023\/A:1020016922473","journal-title":"Eur J Epidemiol"}],"container-title":["European Archives of Oto-Rhino-Laryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-022-07762-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00405-022-07762-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-022-07762-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T17:16:09Z","timestamp":1680282969000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00405-022-07762-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["7762"],"URL":"https:\/\/doi.org\/10.1007\/s00405-022-07762-4","relation":{},"ISSN":["0937-4477","1434-4726"],"issn-type":[{"value":"0937-4477","type":"print"},{"value":"1434-4726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,1]]},"assertion":[{"value":"18 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Juan Maza-Solano has received fees for participation in Advisory Boards (GSK and SANOFI), presentations (ALK, AMPLIFON, MSD-Organon, GSK, NOVARTIS and SANOFI) and participation in clinical trials (GSK, NOVARTIS, SANOFI and AstraZeneca). Leigh Sowerby has received clinical trial support from AstraZeneca, Roche, Optinose, Sanofi and GSK and speaking honoraria for GSK and Sanofi (Advisory board). Isam Alobid is consultant for Menarini, Novartis, Sanofi, GSK, MSD, Salvat, and Roche. All other authors declare they have no competing Interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethics approval for surveying North American respondents was received from Western University Human Research Ethics Board (ID 120154) according to the principles of the Declaration of Helsinki. Approval or waivers were received from other countries as required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained digitally from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}